The estimated Net Worth of Jude Onyia is at least $3.17 Milion dollars as of 13 February 2024. Dr Onyia owns over 1,432 units of Neurocrine Biosciences stock worth over $1,594,658 and over the last 3 years he sold NBIX stock worth over $1,575,341.
Dr has made over 7 trades of the Neurocrine Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 1,432 units of NBIX stock worth $190,370 on 13 February 2024.
The largest trade he's ever made was selling 4,508 units of Neurocrine Biosciences stock on 7 February 2023 worth over $461,168. On average, Dr trades about 1,081 units every 34 days since 2021. As of 13 February 2024 he still owns at least 13,128 units of Neurocrine Biosciences stock.
You can see the complete history of Dr Onyia stock trades at the bottom of the page.
Dr. Jude Onyia Ph.D. is the Chief Scientific Officer at Neurocrine Biosciences.
Jude's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Over the last 22 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... a Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.
neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
Neurocrine Biosciences executives and other stock owners filed with the SEC include: